查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012510

男性健康體檢市場：按產品類型、應用和最終用戶分類 - 2026-2032年全球市場預測

Mens Health Diagnostics Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年男性健康檢查市場價值 162.7 億美元，預計到 2026 年將成長至 181.5 億美元，複合年成長率為 11.69%，到 2032 年將達到 352.9 億美元。

主要市場統計數據
基準年 2025 162.7億美元
預計年份：2026年 181.5億美元
預測年份 2032 352.9億美元
複合年成長率 (%) 11.69%

最新男性健康篩檢概覽，闡述了臨床需求、更嚴格的法規和技術融合如何改變男性健康篩檢的開發和實施。

現代男性健康篩檢趨勢的特徵是臨床需求、技術創新和不斷發展的診療路徑的融合。消費者和臨床醫生越來越需要侵入性更小、特異性更高、且與慢性病管理更緊密結合的診斷方法。同時，隨著監管力度加大和保險公司期望的提高，臨床有效性、真實臨床實踐中的療效證據以及成本效益的標準也日益嚴格。這些趨勢迫使製造商、偵測網路和醫療保健系統重新思考其產品開發時間表和商業化策略。

技術、臨床效用期望和醫療保健服務模式的重大系統性變革，從根本上改變了診斷技術的創新和傳播。

多項變革正在重塑男性健康檢查的設計、檢驗和實施方式，並影響醫療機構的運作模式。精準醫療技術正從概念驗證邁向常規臨床應用，從而能夠針對前列腺疾病和心血管風險等疾病提供更有針對性的篩檢和監測方法。同時，影像技術也在不斷發展，透過先進的軟體、人工智慧驅動的影像解讀以及跨模態整合，在提高診斷準確性的同時，也簡化了工作流程。

關稅政策和貿易措施的變化如何使診斷的整個價值鏈中的採購、定價策略和供應商選址決策變得複雜。

新關稅措施及相關貿易政策的訂定，進一步加劇了診斷供應鏈中供應商、製造商和服務供應商的營運複雜性。資本密整合像系統和專用診斷試劑進口成本的增加，可能會改變醫院和診斷中心的採購決策，進而影響設備更新週期和資金配置。面對不斷上漲的跨國成本，供應商可能需要重新評估區域製造地，協商新的供應商合約條款，或在地採購，以緩解利潤率下降的局面。

將產品模式、醫療保健環境和臨床應用與策略發展和商業化重點連結起來的可操作細分洞察。

精細化的細分觀點能夠清楚地識別出創新和應用壓力最大的領域。在評估產品類型時，影像系統對於結構和功能評估仍然至關重要，每種影像方式——電腦斷層掃描 (CT)、磁振造影(MRI)、核子醫學影像、超音波和 X 光——都發揮獨特的診斷作用。除了成像之外，臨床實驗室檢測透過生物標記檢測和基因檢測，從分子層面提供了更深入的診斷訊息，從而實現更早期的疾病檢測和更個性化的疾病表徵。當這些產品類別在醫療團隊中有效整合時，便可形成互補的診斷路徑，進而增強臨床決策能力。

決定美洲、歐洲、中東、非洲和亞太地區診斷策略應如何調整的區域趨勢和市場狀況。

區域趨勢既影響需求模式，也影響臨床應用路徑。在美洲，整合的醫療保健系統和整合的檢測網路在臨床流程方面展現出顯著的改進，為滿足支付方期望的解決方案創造了有利環境。相較之下，歐洲、中東和非洲（EMEA）的市場環境複雜多樣，法規結構和報銷機制各不相同，因此需要靈活的市場進入策略和針對特定區域的證據策略。同時，亞太地區的特點是基礎設施快速擴張，並高度重視國內製造和區域分銷網路，這影響採購政策和夥伴關係模式。

透過技術整合、證據產生和附加價值服務，在診斷領域確立領導地位的策略競爭行動和能力。

在男性健康篩檢領域，競爭優勢越來越取決於企業能否將技術優勢與可靠的臨床證據和可擴展的服務模式結合。主要企業正著力提升硬體和軟體的協同效應，開發可與分析和決策支援工具互通的影像診斷平台，以減少診斷差異並增強臨床醫師的信心。同時，投資於高特異性生物標記檢測和基因平台的企業則透過宣傳其在早期檢測和預後預測方面更高的準確性來脫穎而出。

在政策變化的背景下，製造商和供應商需要採取切實可行的策略措施來加速產品採用，證明其臨床效用，並確保其商業性韌性。

產業領導企業應優先採取三項策略措施，將新興趨勢轉化為永續的競爭優勢。首先，投資於嚴謹的臨床檢驗項目，將診斷結果與治療決策和患者預後明確關聯起來，從而消除支付方的顧慮，並促進在整個醫療服務路徑中的應用。其次，重組經營模式，透過靈活的資金籌措、捆綁式服務或基於結果的合約來降低應用門檻，從而共用應用風險，並在醫療服務路徑層面展現價值。這些措施將為醫療系統的購買者和支付方提供更清晰的決策指南。

採用穩健的混合方法研究途徑，結合相關人員訪談、臨床文獻綜述、政策分析和情境測試來檢驗見解。

本研究整合了對關鍵相關人員的訪談、對同行評審臨床文獻的系統性回顧以及對監管和支付方政策趨勢的分析，以確保獲得平衡且基於證據的觀點。主要訪談對象包括臨床醫生、實驗室管理人員、技術負責人和採購專家，旨在了解實際情況和推廣應用的障礙。次要分析則著重於近期發表的臨床試驗、指引更新和調查方法論文，以全面檢驗各項技術在診療路徑中的臨床效度和潛在效用。

對診斷趨勢進行明確整合，強調模式整合、複雜的證據要求和具有持久影響的穩健商業化途徑。

總體而言，男性健康篩檢領域正處於一個關鍵的轉折點，技術成熟、支付方審查以及不斷演變的醫療服務模式相互交織，重塑著創新者和醫療服務提供者的優先事項。影像學和臨床檢測的互補性日益增強，為早期發現和更個人化的疾病管理鋪平了道路。同時，對臨床效用和治療過程層面證據的需求不斷成長，促使人們重新評估商業化策略和夥伴關係模式，以確保臨床醫生的認可和支付方的覆蓋範圍。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：男性健康體檢市場：依產品類型分類

  • 醫學影像系統
    • 電腦斷層掃描
    • 磁振造影
    • 核子醫學掃描術診斷
    • 超音波
    • X光
  • 臨床試驗
    • 生物標記檢測
    • 基因檢測

第9章：男性健康體檢市場：依應用領域分類

  • 心血管診斷
  • 糖尿病監測
  • 前列腺癌診斷
  • 泌尿系統疾病的診斷

第10章：男性健康體檢市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 診斷中心
  • 醫院

第11章：男性健康體檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：男性健康體檢市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：男性健康體檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國男性健康體檢市場

第15章：中國男性健康體檢市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Johnson & Johnson
  • Koninklijke Philips NV
  • Myriad Genetics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-431388EE3BC2

The Mens Health Diagnostics Market was valued at USD 16.27 billion in 2025 and is projected to grow to USD 18.15 billion in 2026, with a CAGR of 11.69%, reaching USD 35.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.27 billion
Estimated Year [2026] USD 18.15 billion
Forecast Year [2032] USD 35.29 billion
CAGR (%) 11.69%

A contemporary overview of mens health diagnostics showing how clinical demand, regulatory rigor, and technology convergence are reshaping development and delivery

The modern mens health diagnostics landscape is defined by the convergence of clinical need, technological innovation, and evolving care pathways. Consumers and clinicians increasingly demand diagnostic approaches that are less invasive, more specific, and better integrated with chronic disease management. At the same time, regulatory scrutiny and payer expectations are raising the bar for clinical validation, real-world performance evidence, and cost-effectiveness. These dynamics are prompting manufacturers, laboratory networks, and health systems to rethink product development timelines and commercialization strategies.

Transitioning from legacy diagnostic paradigms, stakeholders are investing in hybrid models that combine imaging modalities with molecular and genetic assays to produce richer diagnostic signals. Integration across care settings is accelerating, with a focus on connecting ambulatory and hospital workflows to deliver timely diagnostic data into treatment decisions. Consequently, strategic planners must balance near-term operational pressures with longer-term investments in interoperability, data analytics, and evidence generation to sustain competitive differentiation and support reimbursement pathways.

Key systemic shifts in technology, clinical utility expectations, and care delivery models that are fundamentally altering diagnostics innovation and adoption

Several transformative shifts are reshaping how mens health diagnostics are designed, validated, and deployed across care settings. Precision technologies have moved beyond proof of concept to routine clinical application, enabling more targeted screening and monitoring approaches for conditions such as prostate disease and cardiovascular risk. Concurrently, imaging has evolved through enhanced software, AI-assisted interpretation, and cross-modality integration that boosts diagnostic accuracy while supporting workflow efficiency.

Another major inflection point is the elevation of value-based care principles, which prioritizes outcomes and long-term cost avoidance. This forces diagnostic developers to demonstrate not just analytic validity, but clinical utility and pathway-level impact. Moreover, the commercialization environment is changing; strategic partnerships between manufacturers, labs, and health systems are becoming essential to scale adoption and secure favorable reimbursement. Taken together, these forces create both opportunities and obligations for innovators to produce robust clinical evidence, drive clinician acceptance, and align diagnostics with evolving care incentives.

How evolving tariff policies and trade measures are complicating procurement, pricing strategies, and supplier footprint decisions across the diagnostics value chain

The introduction of new tariff measures and related trade policies creates an added layer of operational complexity for suppliers, manufacturers, and service providers in the diagnostics supply chain. Increased import costs for capital-intensive imaging systems and specialized assay reagents can alter procurement decisions at hospitals and diagnostic centers, influencing upgrade cycles and capital allocation. Suppliers facing higher cross-border costs may need to reassess regional manufacturing footprints, negotiate new supplier terms, or localize components to mitigate margin erosion.

These policy changes also affect pricing strategies and contract negotiations, because end users operate under constrained budgets and are sensitive to total cost of ownership. As a result, organizations that proactively model tariff impacts and engage stakeholders across procurement, clinical operations, and finance can better preserve access to advanced diagnostics. Furthermore, the need for transparency around cost drivers will intensify, prompting some vendors to offer alternative commercial structures such as managed services, reagent rental, or outcome-based contracting to ease budgetary pressures and maintain adoption momentum.

Actionable segmentation insights linking product modalities, care settings, and clinical applications to strategic development and commercialization priorities

A granular segmentation lens clarifies where innovation and adoption pressures are most acute. When evaluating product types, imaging systems remain critical for structural and functional assessment, with modalities including computed tomography, magnetic resonance imaging, nuclear imaging, ultrasound, and X-ray each serving distinct diagnostic roles. Parallel to imaging, laboratory tests add molecular depth through biomarker assays and genetic testing, enabling earlier detection and more personalized disease characterization. Together, these product classes form complementary diagnostic pathways that bolster clinical decision-making when integrated effectively across care teams.

From an end-user perspective, care settings differ substantially in workflow requirements and capital intensity. Ambulatory surgical centers, clinics, diagnostic centers, and hospitals each demand tailored solutions that address throughput, staffing models, and reimbursement layouts. Applications likewise concentrate clinical and commercial focus on cardiovascular diagnostics, diabetes monitoring, prostate cancer diagnostics, and urological disorder diagnostics, where unmet needs and established care protocols create varied opportunities for tools that deliver actionable insights. Understanding these segment-specific drivers supports targeted development, evidence generation, and commercialization plans that align product capabilities to the realities of each setting and use case.

Regional dynamics and differentiated market realities that determine how diagnostics strategies must adapt across the Americas, Europe/Middle East/Africa, and Asia-Pacific

Regional dynamics shape both demand patterns and the pathway to clinical adoption. In the Americas, integrated health systems and consolidated laboratory networks create fertile ground for solutions that demonstrate measurable pathway improvements and align with payer expectations. In contrast, Europe, the Middle East & Africa presents a heterogeneous landscape where diverse regulatory frameworks and reimbursement mechanisms require adaptable go-to-market approaches and localized evidence strategies. Meanwhile, Asia-Pacific is characterized by rapid infrastructure expansion and a strong emphasis on domestic manufacturing and regional distribution networks, which influences procurement preferences and partnership models.

These geographic distinctions also influence clinical practice norms, investment in imaging capabilities, and the scale-up speed for novel assays. Therefore, companies should tailor regulatory planning, evidence generation, and commercial partnerships to regional realities. Leveraging local clinical champions, investing in region-specific health economics evidence, and adapting service delivery models can accelerate adoption and ensure that innovations translate into sustainable clinical and financial value across markets.

Strategic competitive behaviors and capabilities that define leadership in diagnostics through technology integration, evidence generation, and value-added services

Competitive positioning in mens health diagnostics increasingly depends on the ability to integrate technological strengths with robust clinical evidence and scalable service models. Leading organizations emphasize hardware-software synergy, developing imaging platforms that interoperate with analytics and decision-support tools to reduce interpretation variability and enhance clinician confidence. At the same time, companies investing in high-specificity biomarker assays and genetic platforms are differentiating through claims of earlier detection and greater prognostic precision.

Moreover, successful players are extending their value propositions beyond product delivery to include implementation support, training, and outcomes measurement. This shift reflects the recognition that selling a diagnostic without the associated change management is unlikely to drive widespread clinical uptake. Strategic alliances with laboratory service providers and health systems can amplify reach while easing the burden of evidence generation. Consequently, firms that combine technological excellence with pragmatic commercialization tactics and real-world performance data position themselves favorably in a competitive and evidence-driven marketplace.

Practical strategic initiatives for manufacturers and providers to accelerate adoption, prove clinical utility, and safeguard commercial resilience amid policy shifts

Industry leaders should prioritize a trio of strategic moves to translate emerging trends into durable advantage. First, invest in rigorous clinical validation programs that explicitly tie diagnostic outputs to treatment decisions and patient outcomes, thereby addressing payer concerns and facilitating adoption across care pathways. Second, restructure commercial models to lower adoption barriers through flexible financing, bundled service offerings, or outcome-aligned contracts that share implementation risk and demonstrate pathway-level value. These initiatives will create clearer decision points for health system purchasers and payers.

Third, deepen partnerships across the ecosystem, engaging academic centers, community hospitals, and diagnostic laboratories to accelerate real-world evidence collection and to create reproducible workflows. By coordinating these elements, organizations can shorten time-to-value and foster clinician champions. Finally, maintain an agile supply chain and regulatory strategy to respond quickly to policy shifts and tariff-related disruptions, safeguarding continuity of supply and preserving competitive pricing. Together, these measures will strengthen market resilience and enhance the probability of long-term adoption.

Robust mixed-methods research approach combining stakeholder interviews, clinical literature review, policy analysis, and scenario testing to validate insights

This research synthesizes primary stakeholder interviews, systematic review of peer-reviewed clinical literature, and an analysis of regulatory and payer policy developments to ensure a balanced and evidence-driven perspective. Primary interviews included clinicians, laboratory directors, technology leaders, and procurement specialists to capture operational realities and adoption barriers. Secondary analysis focused on recently published clinical trials, guideline updates, and methodology papers to triangulate the technologies' clinical validity and potential utility within care pathways.

In addition, the methodology incorporated a review of public policy changes and procurement frameworks to assess their implications for capital equipment and consumables. Data synthesis emphasized cross-validation across sources to mitigate single-source bias and to surface consistent themes. Finally, findings were stress-tested through scenario planning to examine how shifts in trade policies, reimbursement environments, and clinical practice might influence strategic priorities and operational decisions for developers and providers.

Conclusive synthesis of diagnostics trends highlighting integration of modalities, elevated evidence requirements, and resilient commercialization pathways for sustained impact

In sum, the mens health diagnostics arena is at a pivotal juncture where technological maturation, payer scrutiny, and shifting care delivery models converge to reshape priorities for innovators and providers. Imaging modalities and laboratory assays are increasingly complementary, creating pathways for earlier detection and more personalized disease management. At the same time, heightened requirements for clinical utility and pathway-level evidence are prompting a reassessment of commercialization strategies and partnership models to secure clinician acceptance and payer coverage.

Looking forward, organizations that proactively build integrated solutions, prioritize transparent evidence development, and adapt commercial structures to meet budgetary realities will be best positioned to capture clinical and economic value. Navigating tariff and policy headwinds requires deliberate supply chain planning and flexible contracting approaches. By aligning technological capabilities with pragmatic evidence and commercialization tactics, stakeholders can accelerate meaningful improvements in diagnostic care while building resilient business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mens Health Diagnostics Market, by Product Type

  • 8.1. Imaging Systems
    • 8.1.1. Computed Tomography
    • 8.1.2. Magnetic Resonance Imaging
    • 8.1.3. Nuclear Imaging
    • 8.1.4. Ultrasound
    • 8.1.5. X Ray
  • 8.2. Laboratory Tests
    • 8.2.1. Biomarker Assays
    • 8.2.2. Genetic Testing

9. Mens Health Diagnostics Market, by Application

  • 9.1. Cardiovascular Diagnostics
  • 9.2. Diabetes Monitoring
  • 9.3. Prostate Cancer Diagnostics
  • 9.4. Urological Disorder Diagnostics

10. Mens Health Diagnostics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals

11. Mens Health Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Mens Health Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Mens Health Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Mens Health Diagnostics Market

15. China Mens Health Diagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Becton Dickinson and Company
  • 16.7. Bio-Rad Laboratories, Inc.
  • 16.8. bioMerieux SA
  • 16.9. Danaher Corporation
  • 16.10. DiaSorin S.p.A.
  • 16.11. Exact Sciences Corporation
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. Hologic, Inc.
  • 16.14. Johnson & Johnson
  • 16.15. Koninklijke Philips N.V.
  • 16.16. Myriad Genetics, Inc.
  • 16.17. QIAGEN N.V.
  • 16.18. Quest Diagnostics Incorporated
  • 16.19. Siemens Healthineers AG
  • 16.20. Sysmex Corporation
  • 16.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENS HEALTH DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY BIOMARKER ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY UROLOGICAL DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MENS HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA MENS HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)